Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: An in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells

Nuclear Medicine and Biology

Volumn 30, Issue 2, 2003, Pages 101-109

  Smith, C Jeffrey ^a   Gali, Hariprasad ^a   Sieckman, Gary L ^b   Hayes, Donald L ^a   Owen, Nellie K ^a   Mazuru, Dana G ^a   Volkert, Wynn A ^a,b   Hoffman, Timothy J ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bombesin; Lanthanide; Lutetium; Prostate

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMIDE; BOMBESIN; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; LUTETIUM; RECEPTOR; UNCLASSIFIED DRUG; 177LU DOTA 8 AMINOOCTANOYLBOMBESIN (7 14) AMIDE; 177LU-DOTA-8-AMINOOCTANOYLBOMBESIN (7-14)-AMIDE; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; CANCER CELL; CONJUGATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; PROSTATE CANCER; PROTEIN SYNTHESIS; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CANCER TRANSPLANTATION; CELL CULTURE; EVALUATION; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PROSTATE TUMOR; RADIOMETRY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; BOMBESIN; FEMALE; HUMANS; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037291708     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00391-8     Document Type: Article

References (41)

1. Anderson C.J., Welch M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 99:1999;2219-2234.
2. Baidoo K.E., Lin K.-S., Zhan Y., Finley P., Scheffel U., Wagner H.N. Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chem. 9:1998;218-225.
3. Bakker W.H., Albert R., Bruns C., Breeman W.A., Hofland L.J., Marbach P., Pless J., Pralet D., Stolz B., Koper J.W. [Indium-111-DTPA-D-Phe-1]octreotide, a potential radiopharmaceutical for imaging somatostatin receptor positive tumors synthesis, radiolabeling, and in vivo validation . Life Sci. 49:1991;1583-1591.
4. Behr T.M., Goldenberg D.M. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? J. Nucl. Med. 37:1996;834-836.
5. Bijsterbosch M.K. Selective drug delivery by means of receptor-mediated endocytosis. Q. J. Nucl. Med. 39:1995;4-9.
6. Boerman O.C., Oyen W.J.G., Corstens F.H.M. Radio-labeled receptor-binding peptides a new class of radiopharmaceuticals . Sem. Nucl. Med. 30:2000;195-208.
7. Brechbiel M.W., Gansow O.A., Atcher R.W., Schlom J., Esteban J., Simpson D.E., Colcher D. Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 25:1986;2772-2781.
8. 4]Bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer. 83:1999;657-663.
9. Breeman W.A.P., Hofland L.J., De Jong M., Bernard B.F., Srinivasan A., Kwekkeboom D.J., Visser T.J., Krenning E.P. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int. J. Cancer. 81:1999;658-665.
10. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents structure, dynamics, and applications . Chem. Rev. 99:1999;2293-2352.
11. Cutler C.S., Smith C.J., Ehrhardt G.J., Tyler T.T., Jurisson S.S., Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biotherapy & Radiopharm. 15:(6):2000;531-545.
12. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 24:1997;368-371.
13. Eckelman W.C., Gibson R.E. The design of site-directed radiopharmaceuticals for use in drug discovery. Burns H.D., Gibson R.E., Dannals R., Siegl P. Nuclear imaging in drug discovery, development, and approval. 1993;Birkhauser, Boston, MA.
14. 2 conjugate for specific targeting of tumors expressing gastrin releasing peptide receptors (GRP-R). J. Nucl. Med. 41:(Suppl 5):2000;119.
15. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12814-12818.
16. Heeg M.J., Jurisson S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc. Chem. Res. 32:1999;1050-1060.
17. 2 (X = 0, β-Ala, 5-Ava, 8-Aoc, or 11-Aun) analogs as potential radiopharmaceuticals for specific-targeting of gastrin releasing peptide (GRP) receptors expressed on human prostate cancer PC-3 cells. J. Nucl. Med. 2001;. (submitted for publication).
18. 105Rh labeled bombesin analogues enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers . J. Labelled Compd. Radiopharm. 40:1997;490-493.
19. Hoffman T.J., Quinn T.P., Volkert W.A. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl. Med. Biol. 28:2001;527-539.
20. Hom R.K., Katzenellenbogen J.A. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals recent developments and encouraging results . Nucl. Med. Biol. 24:1997;485-498.
21. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjugate Chem. 10:1999;254-260.
22. Kvols L.K. Somatostatin receptor imaging of neuroendocrine carcinomas implications for patient management and radiotherapy . Nicolini M., Mazzi U. Technetium, rhenium and other metals in chemistry and nuclear medicine. 1999;153-756 SGEditoriali, Padova, Italy.
23. 0]octreotide in patients . Eur. J. Nucl. Med. 28:2001;1319-1325.
24. 177Lu-DOTA-Y3-Octreotate in a rat model. Int. J. Cancer. 94:2001;873-877.
25. 13,14] bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Life Sci. 37:1985;105-113.
26. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate relation to neoplastic transformation . Cancer Res. 59:(5):1999;1152-1159.
27. 105Rh(III) Complexes with macrocycles. J. Labelled Compd. Radiopharm. 37:1995;426-428.
28. Press O.W., Appelbaum F.R., Early J.F., Bernstein I.D. Radiolabeled antibody therapy of lymphomas. Biol. Ther. Cancer Update. 4:1994;1-13.
29. Qin Y., Ertl T., Cai R.-Z., Halmos G., Schally A.V. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 54:1994;1035-1041.
30. Qin Y., Ertl T., Cai R.-Z., Horvath J.E., Groot K., Schally A.V. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int. J. Cancer. 63:1995;257-262.
31. Rogers B.E., Brechbiel M.W., Kirkman R.L., Clarkson M., Buchsbaum D.J.D. In vitro binding and internalization of an Indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor. Nicolini M. Technetium, rhenium and other metals in chemistry and nuclear medicine. 1999;519-525 SGE Editoriali, Italy.
32. Rogers B.E., Curiel D.T., Mayo M.S., Laffoon K.K., Bright S.J., Buchsbaum D.J. Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector. Cancer Suppl. 8:1997;2419-2424.
33. Seregni E., Chiti A., Bombardieri E. Radionuclide imaging of neuroendocrine tumors biological basis and diagnostic results . Eur. J. Nucl. Med. 25:1998;639-658.
34. Schubiger P.A., Alberto R., Smith A. Vehicles, chelators, and radionuclides choosing the "building blocks" of an effective therapeutic radioimmunoconjugate . Bioconjugate Chem. 7:1996;165-179.
35. 2 an in vitro/in vivo structure-activity relationship study where X = 0, 3, 5, 8, and 11-carbon tethering moieties . Bioconjugate Chem. 2001;. (submitted for publication).
36. 2 a new gastrin releasing peptide receptor (GRPr) targeting radiopharmaceutical . J. Labelled Compd. Radiopharm. 44:2001;706-708.
37. 131I . J. Nucl. Med. 42:2001;967-974.
38. Ugur O., Kostakoglu L., Hui E.T., Fisher D.R., Garmestani K., Gansow O.A., Cheung N.V., Larson S.M. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma dosimetry calculations incorporating cross-organ beta doses . Nucl. Med. Biol. 23:1996;1-8.
39. 99mTc-RP-527, a gastrin releasing peptide (GRP) analogue for visualization of GRP receptor expressing malignancies a feasibility study . Nucl. Med. Commun. 21:2000;21.
40. Van de Wiele C., Dumont F., Broecke R.V., Oosterlinck W., Cocquyt V., Serreyn R., Peers S., Thornback J., Slegers G., Dierckx R.A. Technetium-99m RP525, a GRP analogue for visualization of GRP receptor-expressing malignancies a feasible study . Eur. J. Nucl. Med. 27:2000;1694-1699.
41. Volkert W.A., Hoffman T.J. Therapeutic radiopharmaceuticals. Chem. Rev. 99:1999;2269-2292.